Low Dose Rituximab in Chronic ITP: Still an Option in Resource Limited Settings

Area of Science:

• Immunology
• Hematology
• Pharmacology

Background:

• Immune thrombocytopenic purpura (ITP) pathogenesis involves immune dysregulation and loss of tolerance to platelet antigens.
• Splenectomy is a standard second-line treatment for chronic ITP but faces obstacles in resource-limited settings due to cost and surgical risks.
• Rituximab, a monoclonal antibody, has shown efficacy in ITP treatment at various doses.

Purpose of the Study:

• To evaluate the utility and cost-effectiveness of low-dose Rituximab (100 mg/m² weekly x 4 doses) for chronic ITP in resource-limited settings.
• To assess response rates, time to response, and relapse-free survival in patients treated with low-dose Rituximab.
• To determine the safety and economic viability of this treatment protocol.

Main Methods:

• Prospective study of 21 patients with chronic ITP receiving low-dose Rituximab (100 mg/m² weekly for 4 weeks).
• Evaluation of overall response, complete response (CR), and partial response (PR) rates.
• Monitoring of time to response, relapse-free survival (RFS), and adverse events.

Main Results:

• Overall response rate was 47.6% (10/21), with CR at 33.3% (7/21) and PR at 14.3% (3/21).
• Median time to CR was 75 days; median time to PR was 105 days.
• Cumulative 13-month relapse-free survival was 78%; treatment was well-tolerated in day care, reducing inpatient costs.

Conclusions:

• Low-dose Rituximab is an effective and cost-saving therapeutic option for chronic ITP in resource-limited environments.
• The treatment regimen demonstrated favorable response rates and sustained remission, comparable to higher doses.
• Administration in day care settings further enhances cost-effectiveness and patient accessibility.